GlucoTrack, Inc. (NASDAQ:GCTK) Sees Significant Increase in Short Interest

GlucoTrack, Inc. (NASDAQ:GCTK) was the target of a large increase in short interest in June. As of June 30th, there was short interest totalling 20,300 shares, an increase of 17.3% from the June 15th total of 17,300 shares. Based on an average daily volume of 36,000 shares, the short-interest ratio is presently 0.6 days. Approximately 0.5% of the company’s stock are sold short.

Insiders Place Their Bets

In related news, Director Drew Sycoff bought 36,508 shares of the stock in a transaction on Monday, April 22nd. The shares were acquired at an average price of $6.30 per share, for a total transaction of $230,000.40. Following the purchase, the director now owns 590,251 shares of the company’s stock, valued at $3,718,581.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 17.70% of the company’s stock.

GlucoTrack Stock Performance

GCTK traded down $0.03 during mid-day trading on Monday, reaching $1.64. 2,302 shares of the company traded hands, compared to its average volume of 31,102. The stock has a market capitalization of $8.99 million, a P/E ratio of -0.81 and a beta of 0.06. GlucoTrack has a 52-week low of $0.66 and a 52-week high of $4.95. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.52. The company’s fifty day moving average price is $2.27 and its 200-day moving average price is $1.88.

GlucoTrack (NASDAQ:GCTK) last posted its quarterly earnings data on Wednesday, May 15th. The company reported ($0.60) earnings per share for the quarter.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.